Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes. [electronic resource]
Producer: 20080918Description: 845-53 p. digitalISSN:- 1744-7658
- Adamantane -- adverse effects
- Body Weight -- drug effects
- Clinical Trials, Phase III as Topic -- statistics & numerical data
- Diabetes Mellitus, Type 2 -- blood
- Dipeptidyl Peptidase 4
- Dipeptidyl-Peptidase IV Inhibitors -- adverse effects
- Double-Blind Method
- Drug Therapy, Combination
- Exenatide
- Glucagon-Like Peptide 1 -- pharmacokinetics
- Glucagon-Like Peptide-1 Receptor
- Glycated Hemoglobin -- analysis
- Humans
- Hypoglycemia -- chemically induced
- Hypoglycemic Agents -- adverse effects
- Incretins -- physiology
- Insulin -- metabolism
- Insulin Secretion
- Nausea -- chemically induced
- Nitriles -- adverse effects
- Peptides -- adverse effects
- Pyrazines -- adverse effects
- Pyrrolidines -- adverse effects
- Randomized Controlled Trials as Topic
- Receptors, Glucagon -- drug effects
- Sitagliptin Phosphate
- Triazoles -- adverse effects
- Venoms -- adverse effects
- Vildagliptin
- Vomiting -- chemically induced
No physical items for this record
Publication Type: Journal Article; Review
There are no comments on this title.
Log in to your account to post a comment.